Trial Profile

Phase II/III study of BPM-31510 in subjects with Epidermolysis Bullosa

Status: Planning

Phase of Trial: Phase II/III

Latest Information Update: 05 Nov 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ubidecarenone (Primary)
Indications Epidermolysis bullosa
Focus Adverse reactions; Therapeutic Use

Most Recent Events

31 Oct 2024 According to BPG bio media release, company anticipated to begin this study in 2025.
02 Apr 2023 New trial record
27 Mar 2023 According to BPG bio media release, company has reached a partnership agreement with debra of America for treatment of patients with dystrophic epidermolysis bullosa.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com